| |
Study enrollment |
Follow-up |
|
|
|
|
Predicted phenotypic resistance |
|
|
|
|
Predicted phenotypic resistance |
| Patient |
VL
(ART used)* |
NNRTI
mutations |
NRTI
mutations |
NNRTI |
NRTI |
Months
after enrollment |
VL
(ART used)* |
NNRTI
mutations |
NRTI
mutations |
NNRTI |
NRTI |
| 1 |
3,010 (1b) |
K101E+
V108I+
Y181C |
D67N+
K70R+
M184V+
K219E |
H: NVP
I: EFV; ETR |
H: 3TC
I: AZT
L: d4T; ABC
PL: ddI
S: TDF |
7 |
3,680 (1b) |
K101E+
Y181C |
D67N+
K70R+
M184V+
K219E |
H: NVP
I: EFV
ETR |
H: 3TC
I: AZT
L: d4T; ABC
PL: ddI
S: TDF |
| 3 |
4,310 (1a) |
K101E+
V106M+
G190A |
D67N+
M184V |
H: EFV; NVP
I: ETR |
H: 3TC
L: ABC
PL: ddI
S: d4T; AZT
TDF |
11 |
3,790 (1a) |
K101E+
V106M+
G190A |
D67N+
K70R+
M184V+
K219Q |
H: EFV; NVP
I: ETR |
H: 3TC
I: AZT
L: d4T; ABC
PL: ddI
S: TDF |
| 5 |
1,850 (1a) |
K103N+
V108I |
A62V+
V75I+
M184V |
H: EFV; NVP
S: ETR |
H: 3TC
L: ddI; ABC
S: d4T; AZT
TDF |
6 |
6,150 (1a) |
K103N+
V108I |
A62V+
V75I+
M184V |
H: EFV; NVP
PL: ETR |
H: 3TC
L: ddI; ABC
S: d4T; TDF
AZT |
| 6 |
773 (1a) |
V106M+
G190A+
A98G |
M41L D67N+
K70R+
M184V |
H: EFV; NVP
L: ETR |
H: 3TC
I: d4T, ABC
AZT
L: TDF
ddI |
9 |
4,530 (1a) |
A98G+
V106M+
G190A |
D67N+
K70R+
M184V+
K219Q |
H: EFV; NVP
L: ETR |
H: 3TC
I: AZT
L: d4T
ABC
PL: ddI
S: TDF |
| 7 |
2,530 (1a) |
V106M+
Y188LH |
D67N+
M184V+
K219E |
H: EFV; NVP
L: ETR |
H: 3TC
L: d4T; ABC
AZT
PL: ddI
S: TDF |
12 |
25,000 (1a) |
V90I+
V106M+ Y188L |
M184V |
H: EFV; NVP
L: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
ddI; AZT |
| 12 |
49,900 (1a) |
K103N+
Y181C+
P225H |
M184I |
H: EFV; NVP
I: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
AZT |
6 |
8,540 (1a) |
V90I+
K103N+
Y181C+
P225H |
M184V |
H: EFV; NVP
I: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
AZT; ddI |
| 15 |
18,300 (1a) |
K101E+
Y188L |
M184I |
H: EFV; NVP
L: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
ddI; AZT |
9 |
3,710 (1a) |
K101E+ Y188L |
M184V |
H: EFV; NVP
L: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
ddI; AZT |
18 |
407 (1a) |
K103N+
P225H |
M184V |
H: EFV; NVP
L: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
DDI; AZT |
10 |
937 (1b) |
K103N |
M184V |
H: EFV, NVP
S: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
ddI; AZT |
20 |
1,330 (1a) |
K103N+
V108I |
M184V |
H: EFV; NVP
S: ETR |
H: 3TC
PL: ABC
S: d4T; DDI
TDF; AZT |
10 |
3,010 (1a) |
K103N+
V108I |
M184V |
H: EFV; NVP
S: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
ddI; AZT |
23 |
955 (1b) |
V106M |
A62V+
M184V |
H: EFV; NVP
PL: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
DDI; AZT |
11 |
2,540 (1b) |
V106M+ E138A |
A62V+
M184V |
H: EFV; NVP
L: ETR |
H: 3TC
PL: ABC
S: d4T; TDF
ddI; AZT |
30 |
1,130 (1a) |
K103N |
--- |
H: EFV; NVP
S: ETR |
S: all drugs |
9 |
15,700 (1a) |
K103N |
V75I |
H: EFV; NVP
S: ETR |
PL: d4T; ddI
S: 3TC; TDF
ABC; AZT |
35 |
83,000 (1a) |
Wild type |
Wild type |
S: all drugs |
S: all drugs |
9 |
2,670 (1a) |
V106M |
K70R+
M184V |
H: EFV; NVP
PL: ETR |
H: 3TC
PL: ABC; AZT
S: d4T; TDF;
ddI |
40 |
4 660 |
Not amplifiable |
Not amplifiable |
--- |
--- |
9 |
31,300 |
K103N+
P225H |
V75I+
M184V |
H: EFV; NVP
L: ETR |
H: 3TC
L: ABC; DDI
S: d4T; AZT;
TDF |
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI; VL, virus load (copies/mL); ART, antiretroviral therapy; EFV, Efavirenz; NVP, Nevirapine; ETR,
Etravirine; 3TC, Lamivudine; d4T, Stavudine; TDF, Tenofovir; ABC, Abacavir; AZT, Zidovudine; DDI, Didanosine; S, Susceptible; PL, potentially low-level of resistance;
L, low-level resistance; I, intermediate level of resistance; H, High level of resistance; Line 1a, EFV + 3TC + d4T; Line 1b, NVP + 3TC + d4T
Underlined mutations = lost mutations; Bolded mutations=gained mutations and Italic mutations=Minor mutations, for Etravirine, according to the IAS USA-2009 list.
Background colors for predicted phenotypic resistance were: White if susceptible or potentially-low; Light gray if low or intermediate and dark gray if highly resistant. |
